The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis is a paper indexed in ScholarIQ from OpenAlex.
How many citations does The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis have?
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis has 67 citations in the OpenAlex counts ScholarIQ stores.
When was The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis published?
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis has 2016 year in the ScholarIQ index.
What is the open-access status of The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis?
The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis has green oa status in the ScholarIQ index.
What is the DOI of The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis?
The DOI for The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis is on the source record.
What is the PMID of The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis?
The PMID for The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis is on the source record.
What is the OpenAlex record for The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis?
The OpenAlex for The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis is on the source record.